Aleksei N. Kozhevnikov

Aleksei N. Kozhevnikov

Auto-generated profile, based on publicly available information

Aleksei N. Kozhevnikov

H. Turner National Medical Research Center for Children’s Orthopedics and Trauma Surgery

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2023 in Pediatric Traumatology, Orthopaedics and Reconstructive Surgery
Verified
Journal Article
Open access
PDF file
AKAleksei N. Kozhevnikov
Aleksei N. Kozhevnikov
DBDmitrii B. Barsukov
Dmitrii B. Barsukov
AGAigul R. Gubaeva
Aigul R. Gubaeva
BACKGROUND: Aseptic necrosis of the femoral head in children remains a subject of great interest among specialists, despite its long history of study. The LeggCalvPerthes disease is the most common form of aseptic necrosis of the femoral head in children. The necrotic lesion in the femoral head results from the blockage of the arterial blood supply to the epiphysis, leading to its infarction. Some children experience a more aggressive disease course, with signs of osteoarthritis, which can result in the early development of coxarthrosis. Numerous publications have demonstrated the successful use of bisphosphonates in adult patients with aseptic necrosis of the femoral head. AIM: To generalize data on the use of bisphosphonates in children with the LeggCalvPerthes disease presenting with signs of osteoarthritis through the analysis of contemporary global literature. MATERIALS AND METHODS: A literature search was conducted in the open databases of PubMed, Science Direct, and Google Scholar, and the analysis depth spanned 20 years. The search terms used included LeggCalvPerthes disease, aseptic (avascular) necrosis of the femoral head, and bisphosphonates. The review encompassed the literature on bisphosphonates, their biological action, effectiveness of their use in patients with aseptic necrosis of the femoral head, and results of our research. RESULTS: Studies on the efficacy of bisphosphonates in children with LeggCalvPerthes disease are limited. Currently, the effect of bisphosphonates on disease course and outcome is unknown. Despite this, mechanisms of chronic inflammation are increasingly mentioned in the literature, which may directly or indirectly influence the clinical course and outcome of the disease. The key is the hyperactivity of osteoclasts in osteonecrosis. The experience of using bisphosphonates in adult patients with aseptic necrosis of the femoral head had positive results in preventing the progression of the deformity of femoral head deformity. CONCLUSIONS: Bisphosphonates are specific inhibitors of osteoclast activity, which has been used in many diseases. The results and inferences of using bisphosphonates in children with LeggCalvPerthes disease will lead to the formulation of a new treatment algorithm.

1 January 2017 in Bulletin of Siberian Medicine
Verified
Journal Article
Open access
PDF file
АКАлексей Николаевич Кожевников
Алексей Николаевич Кожевников
НПНина Анатольевна Поздеева
Нина Анатольевна Поздеева
МКМихаил Александрович Конев
Михаил Александрович Конев
ОМОльга Николаевна Маричева
Ольга Николаевна Маричева
КАКонстантин Александрович Афоничев
Константин Александрович Афоничев
ГНГеннадий Айзикович Новик
Геннадий Айзикович Новик
Рентгенодиагностика хронического олигоартрита у детей

18 July 2021 in Bulletin of Siberian Medicine
Verified
Journal Article
Open access
PDF file
AKA. N. Kozhevnikov
A. N. Kozhevnikov
NPN. A. Pozdeeva
N. A. Pozdeeva
MNM. S. Nikitin
M. S. Nikitin
OMO. N. Maricheva
O. N. Maricheva
TMT. V. Murashko
T. V. Murashko
GNG. A. Novik
G. A. Novik
Оценка эффективности локальной стероидной терапии у детей с олигоартикулярным вариантом ювенильного артрита: результаты ретроспективного исследования

12 December 2025 in Pediatric Traumatology, Orthopaedics and Reconstructive Surgery
Verified
Journal Article
Closed access
PDF file
AKAleksey N. Kozhevnikov
Aleksey N. Kozhevnikov
EMEvgenii V. Melchenko
Evgenii V. Melchenko
NSNikita A. Shabaldin
Nikita A. Shabaldin
VKVladimir Kenis
Vladimir Kenis
Multiple epiphyseal dysplasia is a group of musculoskeletal disorders characterized by genetic heterogeneity in both inheritance patterns and clinical manifestations. One of the most frequent and unfavorable outcomes of this dysplasia is hip osteoarthritis with displacement of the femoral head. Clinical and instrumental manifestations of osteoarthritis in children with multiple epiphyseal dysplasia may often mimic juvenile idiopathic arthritis. Nonsteroidal anti-inflammatory drugs are considered to be pathogenetically justified; however, their efficacy is not always sufficient. The impact of immunosuppressive therapy on the course of osteoarthritis in children with multiple epiphyseal dysplasia has not been previously studied. This article presents a clinical case of successful use of the anti-inflammatory drug tofacitinib, a selective immunosuppressant, in an 11-year-old child with type 4 multiple epiphyseal dysplasia. The disease course was complicated by osteoarthritis and displacement of the right femoral head. No evidence supporting juvenile idiopathic arthritis was identified. Long-term therapy with nonsteroidal anti-inflammatory drugs failed to produce the desired effect. In combination with mechanotherapy, tofacitinib (a Janus kinase inhibitor) 10 mg/day in two divided doses resulted in the resolution of osteoarthritic manifestations and prevention of progression of femoral head displacement. Janus kinase inhibitors are well-known as targeted synthetic disease-modifying antirheumatic drugs. These inhibitors are comparable in efficacy to traditional genetically engineered biological agents used to treat juvenile idiopathic arthritis. Their mechanism of action is based on selective inhibition of intracellular signaling pathways of proinflammatory cytokines. The experience of using selective Janus kinase inhibitors in rheumatology may justify their application in children with skeletal dysplasias complicated by osteoarthritic changes. Type 4 multiple epiphyseal dysplasia is a skeletal dysplasia that inevitably leads to hip osteoarthritis and femoral head displacement. The use of Janus kinase inhibitors in children with this dysplasia accompanied by osteoarthritic manifestations may therefore be justified and highly promising.

18 April 2025 in Pediatric Traumatology, Orthopaedics and Reconstructive Surgery
Verified
Journal Article
Open access
PDF file
AKAleksey N. Kozhevnikov
Aleksey N. Kozhevnikov
EDElena A. Derkach
Elena A. Derkach
APAleksandra A. Porohova
Aleksandra A. Porohova
SLSergey A. Lukyanov
Sergey A. Lukyanov
ЛАЛукьянов Сергей Андреевич
Лукьянов Сергей Андреевич
BACKGROUND: Juvenile idiopathic arthritis is the most common chronic inflammatory musculoskeletal disease in children. Its most prevalent clinical subtype is oligoarthritis. Pigmented villonodular synovitis, also known as tenosynovial giant cell tumor, is a rare benign synovial disorder, which may clinically resemble oligoarthritis. Differential diagnosis between juvenile idiopathic arthritis and pigmented villonodular synovitis is challenging. Intra-articular steroids used in juvenile idiopathic arthritis therapy may induce negative effects in patients with pigmented villonodular synovitis. Orthopedic and surgical procedures used to rule out pigmented villonodular synovitis are burdensome for children. Magnetic resonance imaging may yield similar findings for both conditions at early stages. Several studies revealed that serum calprotectin is a promising biomarker for juvenile idiopathic arthritis. AIM: To assess synovial fluid calprotectin concentrations in children with oligoarthritis and pigmented villonodular synovitis. METHODS: The synovial fluid concentrations of calprotectin, interleukin-6, and tumor necrosis factor-alpha in 42 children with oligoarthritis and 12 children with diffuse pigmented villonodular synovitis of the knee joint were obtained by enzyme-linked immunosorbent assay. In patients with juvenile idiopathic arthritis, cytokine levels were determined at disease onset, and prior to therapeutic and diagnostic arthroscopy in those with pigmented villonodular synovitis. RESULTS: Synovial calprotectin significantly increased in children with oligoarthritis (108 [28.2; 237] μg/mL) compared to those with pigmented villonodular synovitis (1.53 [1.26; 1.69] μg/mL; p 0.001). No statistically significant differences were found in synovial tumor necrosis factor-alpha and interleukin-6 concentrations between patients with juvenile idiopathic arthritis and those with pigmented villonodular synovitis. ROC analysis showed a synovial calprotectin threshold of 2.9 μg/mL for the diagnosis of juvenile idiopathic arthritis (AUC = 0.996 ± 0.00479; 95% CI: 0.926–1.000). CONCLUSION: In children, the differential diagnosis of oligoarthritis is often complicated by clinically similar nonrheumatic joint disorders. The main synovial proinflammatory markers cannot be used for the differential diagnosis of juvenile idiopathic arthritis and pigmented villonodular synovitis. Synovial calprotectin concentration is a promising biomarker of juvenile idiopathic arthritis.

11 April 2024 in Pediatric Traumatology, Orthopaedics and Reconstructive Surgery
Verified
Journal Article
Closed access
PDF file
Tatiana MarkovaTatiana Markova
Tatiana Markova
VKVladimir Kenis
Vladimir Kenis
AKAleksei N. Kozhevnikov
Aleksei N. Kozhevnikov
YBYuriy V. Buklemishev
Yuriy V. Buklemishev
DGDarya V. Gorodilova
Darya V. Gorodilova
EDElena L. Dadali
Elena L. Dadali
BACKGROUND: Multicentric carpotarsal osteolysis (MCTO) syndrome is a rare autosomal dominant disease of skeletal dysplasias caused by heterozygous missense variants in MAFB. Clinical manifestations of the disease are characterized by pain, swelling, and hand and foot deformities as a result of progressive osteolysis of the carpal and tarsal bones. Kidney insufficiency also developed in some patients. CLINICAL CASES: Three Russian patients aged 2–39 years with MCTO syndrome caused by pathogenic variants c.176CT, c.184AG, c.203CT in MAFB are presented. All cases were sporadic. Two of our patients with MCTO were typically observed for several years with a diagnosis of juvenile idiopathic arthritis. All patients underwent phenotypic analysis using standard methods, radiography of the upper and lower extremities, ultrasonography of the kidneys, blood and urine tests to assess renal function, and molecular tests to clarify the diagnosis. Molecular genetic analysis included direct automatic Sanger sequencing of MAFB (NM_005461.5). DISCUSSION: The clinical manifestations of the disease in the patients included deformities and shortening of the hands and feet and typical signs of osteolysis of the metacarpal and metatarsal bones on radiographs. One of the examined patients had proteinuria in early childhood. Considering the rarity of MCTO syndrome, a description of the clinical and radiological characteristics of newly identified cases of the disease will help optimize its diagnosis and multidisciplinary observation of patients and improve the quality of medical and genetic counseling for affected families. CONCLUSIONS: The first clinical manifestations of MCTO syndrome are characterized by significant similarities with those of juvenile arthritis. For their differential diagnosis, a thorough radiographic analysis of the hands and feet for osteolysis is necessary. Early diagnosis of MCTO syndrome is essential because in recent years intensive research aimed at developing therapy for diseases caused by dysfunction of the RANK/RANKL signaling pathway, in which the protein product of MAFB functions.